Due to recent acquisitions, diagnostic criteria for the antiphospholipid/cofactors syndrome need to be improved. In the absence of a “common biological denominator”, the best approach should be based on a scoring system mixing clinical and immunological items. APS might be composed of different biological subsets characterized by antibodies directed to various cofactors. Among clinical subsets, the categorization between “primary” and SLE-related APS may be difficult to achieve. Contrasting with the innumerable conditions associated with the presence of aPL, the diversity of “true” secondary APS should probably be restrained. Attempts at establishing correlations between clinical and biological APS subsets will require further studies.
AshersonRAThe ‘primary’ antiphospholipid syndrome: major clinical and serological features. Medicine1989; 68: 366–374
8.
HarrisEN. A reassessment of the antiphospholipid syndrome. J Rheumatol1990; 17: 733–735
9.
PetriM. Epidemiology of the antiphospholipid syndrome. In: AshersonRACerveraRPietteJCShoenfeldY (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton1996, pp 13–28
10.
HarrisENPierangeliSBirchD. Anticardiolipin wet workshop report—Fifth international symposium on antiphospholipid antibodies. Am J Clin Pathol1994; 101: 616–624
11.
BrandtJTBarnaLKTriplettDA. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for identification of lupus anticoagulants. Thromb Haemost1995; 74: 1597–1603
12.
Alarcon-SegoviaDAntiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine1989; 68: 353–365
13.
Alarcon-SegoviaDPreliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum1992; 21: 275–286
14.
Alarcon-SegoviaD. Clinical manifestations of the antiphospholipid syndrome. J Rheumatol1992; 19: 1778–1781
15.
PietteJCWechslerBBletryOGodeauP. Quels critères pour le diagnostic du syndrome des antiphospholipides?. Rev Med Interne1993; 14: 799–303
16.
JennetteJCNomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum1994; 37: 187–192
17.
LieJT. Nomenclature and classification of vasculitis: plus ça change, plus c'est la même chose. Arthritis Rheum1994; 37: 181–186
18.
AshersonRAPietteJCCerveraR. ‘Primary’, ‘Secondary’, ‘Catastrophic’, and other variants of the antiphospholipid syndrome. In: AshersonRACerveraRPietteJCShoenfeldY (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 249–258
19.
TanEMThe 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277
20.
PietteJCWechslerBFrancesCGodeauP. Systemic lupus erythematosus and the antiphospholipid syndrome: reflections about the relevance of ARA criteria. J Rheumatol1992; 19: 1835–1837
PapoTTlymphocytes subsets in primary antiphospholipid syndrome. J Rheumatol1994; 21: 2242–2245
26.
PapoTExpression of soluble Fas mRNA in mononuclear cells correlates with apoptosis levels in vitro in SLE, but not in primary antiphospholipid syndrome. Lupus1996; 5:5 (abstract)
27.
PietteJCNonlesional sun-exposed Lupus Band test is negative in primary antiphospholipid syndrome. Lupus1995; 4 (Suppl 2): 24 (abstract)
28.
WilsonWAFamilial anticardiolipin antibodies and C4 deficiency genotypes that coexist with MHC DQB1 risk factors. J Rheumatol1995; 22: 227–235
29.
BiousseVPietteJC. Genetic aspects of the primary antiphospholipid syndrome. Nouv Rev Fr Hematol1995; 37 (Suppl II): S65–S67
30.
BentolilaSHigh frequency of C4 ‘null’ alleles in primary antiphospholipid syndrome. Ann Med Interne1996; 147: 115–116
31.
RuffattiAAntiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome?. J Rheumatol1994; 21: 2162–2163
32.
BessisDTrousseau's syndrome with nonbacterial thrombotic endocarditis: Pathogenic role of antiphospholipid syndrome. Am J Med1995; 98: 511–513
33.
PietteJC. What is going to happen tomorrow regarding the antiphospholipid syndrome?. Ann Med Interne1995; 146: 555–558
34.
RosoveMHBrewerPMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med1992; 117: 303–308
35.
ViannaJLComparison of the primary and secondary antiphospholipid syndrome: a european multicenter study of 114 patients. Am J Med1994; 96: 3–9
36.
LevineSRRecurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol1995; 38: 119–124
37.
KhamashtaMAThe management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med1995; 332: 993–997
38.
RavelliACaporaliRMontecuccoCMartiniA. The antiphospholipid syndrome in childhood. J Rheumatol1996; 23: 1121–1122
39.
HageMLFetal renal vein thrombosis, hydrops fetalis, and maternal lupus anticoagulant. A case report. Prenat Diagn1994; 14: 873–877
40.
Antiphospholipid Antibodies in Stroke Study Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology1993; 43: 2069–2073
41.
ManoussakisMNHigh prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol1987; 69: 557–565
42.
SebastianiGDGaleazziM. Immunogenetics of the antiphospholipid syndrome. In: AshersonRACerveraRPietteJCShoenfeldY (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 49–58
43.
KingsmoreSFClinical and genetic features of 12 families with an inherited primary antiphospholipid antibody syndrome. Arthritis Rheum1994; 37 (Suppl): S296 (abstract)
AshersonRA. The catastrophic antiphospholipid syndrome. J Rheumatol1992; 19: 508–512
49.
FrancesCMultiple subungual splinter haemorrhages in the antiphospholipid syndrome: a report of five cases and review of the literature. Lupus1994; 3: 123–128
50.
BickRLBakerWF. Antiphospholipid and thrombotic syndromes. Semin Thromb Hemost1994; 20: 3–15
51.
CerveraRHigh prevalence of significant heart valve lesions in patients with the ‘primary’ antiphospholipid syndrome. Lupus1991; 1: 43–47
52.
FrancesCBletryOPietteJC. Dermatologic manifestations in the antiphospholipid syndrome. In: AshersonRACerveraRPietteJCShoenfeldY(Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 201–211
53.
FrancesCSneddon's syndrome with or without antiphospholipid antibodies: a comparative study. Lupus1996; 5:5 (abstract)
54.
AshersonRAPietteJC. The catastrophic antiphospholipid syndrome: 1996. Acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus1996; 5:5
55.
Alarcon-SegoviaDCabralAR. The antiphospholipid/cofactors syndromes. J Rheumatol1996; 23: 1319–1322
56.
KandiahDAKrilisSA. Immunology and methods of detection of antiphospholipid antibodies. In: AshersonRACerveraRPietteJCShoenfeldY(Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, 29–48
57.
HuntJEA phospholipids-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus1992; 1: 75–51
58.
GharaviAESammaritanoLRWenJYElkonKB. Induction of antiphospholipid autoantibodies by immunization with beta2 Glycoprotein-I (apolipoprotein-H). J Clin Invest1992; 90: 1105–1109
59.
OostingJDAntiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood1993; 81: 2618–2625
60.
RoubeyRAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other antiphospholipid autoantibodies. Blood1994; 84: 2854–2867
61.
GalliMAnticoagulant activity of β2-Glycoprotein I is potentiated by a distinct subgroup of anti-cardiolipin antibodies. Thromb Haemost1992; 68: 297–300
62.
SugiTMcIntyreJA. Auoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood1995; 86: 3083–3089
63.
ViardJPAmouraZBachJF. Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med1992; 93: 181–186
64.
CabiedesJCabralARAlarcon-SegoviaD. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol1995; 22: 1899–1906
65.
HorbachDADerksenRHWMde GrootPG. The presence of anti-β2-glycoprotein I and anti-prothrombin antibodies and their correlations with venous and arterial thrombosis. Ann Med Interne1996; 147 (Suppl I): 42–43
66.
CabralARCabiedesJAlarcon-SegoviaD. Antibodies to phospholipid-free β2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol1995; 22: 1894–1898
FrancesCPietteJCViardJPTourbahA. Anti-β2 glycoprotein I in Sneddon's syndrome. Dermatology1993; 186: 273
69.
VaaralaOAntibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost1996; 75: 456–459
70.
CabralARCabiedesJAlarcon-SegoviaD. Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes. J Autoimmunity1990; 3: 773–787
71.
KarmochkineMAntiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheum1992; 10: 603–605
72.
BerardMChantomeRMarcelliABoffaMC. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. Association with thrombosis and vascular cutaneous diseases. J Rheumatol1996; 23: 1369–1374
73.
LarochePAdvantage of using both anionic and zwitterionic antigens for the detection of antiphospholipid antibodies. Am J Clin Path1996; (in press)
74.
FabrisFSpecific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol1994; 53: 232–236
75.
EscalanteABreyRLMitchellBDJr.DreinerU. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med1995; 98: 559–565
76.
PierangeliSSInduction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost1995; 74: 1361–1367
77.
HarrisENThrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med1986; 146: 2153–2156
78.
LoizouSAssociation of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Q J Med1988; 168: 525–531
79.
PeacockNWLevineSP. The lupus anticoagulant-hypoprothrombinemia syndrome—Case report. Am J Med Sci1994; 307: 346–349
80.
PietteJCCacoubPWechslerB. Renal manifestations of the antiphospholipid syndrome. Sem Arthritis Rheum1994; 23: 357–366
81.
BrunetPAntiphospholipids in hemodialysis patients: Relationship between lupus anticoagulant and thrombosis. Kidney Int1995; 48: 794–800
82.
QuintarelliCPrevalence of lupus anticoagulant in patients with cirrhosis: Relationship with beta-2-glycoprotein I plasma levels. J Hepatol1994; 21: 1086–1091
83.
ZuckermanEIncreased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer1995; 72: 447–451
84.
LoizouSAWalportMJDaviesKA. The antiphospholipid syndrome in infectious diseases. In: AshersonRACerveraRPietteJCShoenfeldY (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 267–284
85.
KerleauJMPrevalence and evolution of anticardiolipin antibodies in giant cell arteritis during corticosteroid therapy. A prospective study of 20 consecutive cases. Br J Rhematol1994; 33: 648–650
86.
MartinuzzoMEForastieroRRCarrerasLO. Anti-β2 glycoprotein 1 antibodies: detection and association with thrombosis. Br J Haematol1995; 89: 397–402
87.
McNallyTThe use of an anti-β2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Brit J Haematol1995; 91: 471–473
88.
GharaviAECharacteristics of human immunodeficiency virus and chloipromazine induced antiphospholipid antibodies: effect of β2-glycoprotein I on binding to phospholipid. J Rheumatol1994; 21: 94–99
89.
BeckerJCWinklerBKlingenSBrockerEB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer1994; 73: 1621–1624
90.
OshiroBTAntiphospholipid antibodies and fetal death. Obstet Gynecol1996; 87: 489–493
91.
LapercheSAssociation of antimitochondrial antibodies type 5 and anti-β2 glycoprotein I antibodies in the antiphospholipid syndrome. J Rheumatol1994; 21: 1678–1683
92.
MeyerOAntiphospholipid antibodies: a disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosus (SLE). Comparison with a group of 91 patients with antinuclear antibody positive SLE. J Rheumatol1987; 14: 502–506
93.
DaviesKAAthanassiouPLoizouSA. Thrombocytopenia and other haematological abnormalities in the antiphospholipid syndrome. In: AshersonRACerveraRPietteJCShoenfeldY (Eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton, 1996, pp 219–234
